

Imugene Receives \$1.1 million in Research and Development Tax Refund

MELBOURNE Australia 10 October 2017: Imugene Limited (ASX: IMU), an immuno-oncology company has received a research and development tax refund of \$1,136,765 as part of the Australian government's R&D incentive program.

For further information please contact:

Leslie Chong
Chief Executive Officer
E: Leslie.Chong@Imugene.com

About Imugene (ASX:IMU)

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

Imugene is also building a pipeline of small molecule immuno-oncology drugs which modulate the bioavailability of arginine in the tumour microenvironment. Arginine is a critical amino acid for the health of cancer fighting T-cells and depletion of it limits the effectiveness of T-cells to fight tumours.